A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid
- Indications Bone metastases; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 01 Mar 2021 Results (n=302) of post hoc analysis identifying the risk factors of Skeletal related events in patients with bone metastasis from NSCLC, published in the Supportive Care in Cancer
- 19 Nov 2020 According to a BeiGene media release, the approval of XGEVA for the prevention of skeletal-related events (SREs) in patients with bone metastasis from solid tumors and MM was based on clinical results from four randomized international trials (NCT00321464, NCT00330759, NCT00321620, and NCT01345019).
- 19 Nov 2020 According to a BeiGene media release, the China National Medical Products Administration (NMPA) has approved XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in patients with multiple myeloma (MM).